ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?
by Renee Jackson · The Cerbat GemShares of ImmuCell Corporation (NASDAQ:ICCC – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.59 and traded as high as $10.20. ImmuCell shares last traded at $10.12, with a volume of 33,471 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell has a consensus rating of “Sell”.
Check Out Our Latest Report on ImmuCell
ImmuCell Stock Performance
The stock has a market capitalization of $91.59 million, a price-to-earnings ratio of -168.64 and a beta of 0.50. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. The stock’s 50-day simple moving average is $7.60 and its 200 day simple moving average is $6.59.
ImmuCell (NASDAQ:ICCC – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.
Hedge Funds Weigh In On ImmuCell
Large investors have recently modified their holdings of the stock. Militia Capital Management LLC acquired a new position in shares of ImmuCell during the first quarter worth approximately $114,000. Steadtrust LLC acquired a new stake in ImmuCell in the third quarter worth $198,000. Mesirow Financial Investment Management Inc. raised its holdings in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of ImmuCell by 3.2% during the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 1,749 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 2,907 shares during the period. 13.47% of the stock is currently owned by institutional investors and hedge funds.
ImmuCell Company Profile
ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.
The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.